Abeona Therapeutics (ABEO) AI Stock Analysis

• Market Cap: $305.92M
• Dividend Yield: N/A
• Average Volume (3M): 1.05M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.86
• Revenue Growth: -100.00%
• EPS Growth: 30.33%
• Country: US
• Employees: 136
• Sector: Healthcare
• Sector Strength: 46
• Industry: Biotechnology
• EPS (TTM): -0.24
• Shares Outstanding: 51,156,734
• 10 Day Avg. Volume: 792,758
• 30 Day Avg. Volume: 1,047,604
• PEG Ratio: <0.01
• Price to Book (P/B): 0.90
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.56
• Enterprise Value/Market Cap: 0.14
• Enterprise Value/Revenue: 7.68
• Enterprise Value/Gross Profit: -26.01
• Enterprise Value/Ebitda: -0.21
• 1Y Price Target: $21.10
• Price Target Upside: 266.96% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 50 Neutral
• Price Target: ―

Abeona Therapeutics faces substantial financial challenges with no current revenue and ongoing losses, impacting its overall score. However, the promising potential for FDA approvals and significant revenue opportunities from new therapies provide a positive outlook. Despite bullish technical signals, the high RSI suggests caution. The stock's valuation remains unattractive due to its negative P/E ratio, but strong earnings call projections and adequate cash reserves offer some optimism for future performance.

Positive Factors

Commercial Availability

ZEVASKYN is now officially commercially available in the U.S. after the activation of Ann & Robert H. Lurie Children’s Hospital of Chicago as the first of five qualified treatment centers.

Earnings Forecast

Abeona anticipates becoming profitable in early 2026, with projections indicating potential profitability before the end of this year depending upon the trajectory of the ZEVASKYN launch.

Financial Stability

Abeona announced the sale of its Rare Pediatric Disease Priority Review Voucher for gross proceeds of $155M, providing sufficient cash for more than two years of operating expenses.

Negative Factors

Patient Treatment Challenges

The ability to reach break-even at a modest throughput of approximately 3 patients per month indicates a strong potential for profitability.

Pricing Concerns

ZEVASKYN's list price is significantly higher than initially forecasted, suggesting a strong revenue potential for Abeona.

Abeona Therapeutics Business Overview & Revenue Model

Company Description

Abeona Therapeutics Inc. (ABEO) is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies for serious genetic diseases. Based in the United States, the company's primary areas of focus include rare and life-threatening conditions such as recessive dystrophic epidermolysis bullosa (RDEB) and other genetic disorders. Abeona's core product candidates leverage advanced gene editing and cell therapy technologies aimed at providing transformative treatments for patients with unmet medical needs.

How the Company Makes Money

Abeona Therapeutics generates revenue primarily through strategic partnerships, grants, and licensing agreements related to its proprietary technologies and product candidates. The company may receive upfront payments, milestone payments, and royalties from these collaborations as their therapeutic products progress through clinical development and towards commercialization. Abeona's focus on rare genetic disorders often attracts funding from non-profit organizations and governmental bodies interested in supporting the advancement of novel treatments for these conditions. Additionally, successful commercialization of their therapies, if achieved, would provide direct revenue from product sales.

Abeona Therapeutics Financial Statement Overview

Summary

Abeona Therapeutics exhibits significant financial challenges, characterized by consistent losses, lack of revenue growth, and negative cash flows. Despite manageable debt levels, the company's financial health is at risk without a turnaround in operational performance and revenue generation.

Income Statement

Abeona Therapeutics shows a concerning trend with no revenue in the latest year, indicating potential challenges in product commercialization. The persistent negative net profit margin and declining EBIT and EBITDA margins reflect ongoing operational struggles and financial losses over recent years.

Balance Sheet

The balance sheet indicates a moderate financial position with a relatively low debt-to-equity ratio, suggesting manageable leverage. However, the shrinking equity base and decreasing return on equity highlight challenges in value creation and financial returns for investors.

Cash Flow

Cash flow analysis reveals negative free cash flow growth and a declining operating cash flow to net income ratio, underscoring liquidity challenges. The reliance on financing activities suggests potential sustainability concerns without generating positive cash flow from operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	3.50M	1.41M	3.00M	10.00M
Gross Profit	-1.67M	-2.91M	1.90M	964.00K	-1.46M	-20.14M
EBITDA	-36.93M	-64.21M	-50.57M	-34.38M	-76.80M	-74.52M
Net Income	-44.19M	-63.73M	-54.19M	-31.81M	-84.94M	-84.23M
Balance Sheet
Total Assets	99.36M	108.93M	64.00M	64.21M	79.59M	151.20M
Cash, Cash Equivalents and Short-Term Investments	84.16M	97.72M	52.23M	52.15M	45.02M	95.03M
Total Debt	23.98M	23.05M	5.40M	7.63M	9.38M	8.73M
Total Liabilities	57.97M	64.90M	49.18M	37.45M	37.22M	48.65M
Stockholders Equity	41.40M	44.03M	14.83M	26.76M	42.37M	102.55M
Cash Flow
Free Cash Flow	-63.00M	-58.46M	-37.34M	-43.61M	-69.82M	-36.35M
Operating Cash Flow	-59.88M	-56.02M	-37.01M	-43.48M	-65.67M	-35.02M
Investing Cash Flow	-27.21M	-39.24M	208.00K	-23.96M	66.06M	-83.71M
Financing Cash Flow	85.47M	104.14M	37.06M	43.17M	24.86M	1.94M

Abeona Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.75
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ABEO, the sentiment is Negative. The current price of 5.75 is below the 20-day moving average (MA) of 6.16, below the 50-day MA of 5.93, and below the 200-day MA of 5.77, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 41.82 is Neutral, neither overbought nor oversold. The STOCH value of 32.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ABEO.

Abeona Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CMPX	60 Neutral	$371.98M	―	-41.31%	―	―	-7.93%
ABEO	50 Neutral	$305.92M	―	-271.78%	―	-100.00%	30.33%
Sector *	48 Neutral	AU$2.44B	3.89	-64.25%	2.90%	35.15%	13.63%
AVIR	47 Neutral	$296.96M	―	-30.47%	―	―	-22.66%
ATXS	44 Neutral	$318.85M	―	-32.89%	―	―	27.92%
ITOS	41 Neutral	$384.27M	―	-23.68%	―	―	14.60%
CADL	33 Underperform	$258.62M	―	-98.14%	―	―	-33.79%

Abeona Therapeutics Corporate Events

Abeona Therapeutics Hosts Conference Call and Webcast

On April 29, 2025, Abeona Therapeutics Inc. hosted a conference call and webcast, providing a presentation that was furnished as Exhibit 99.1 to a Current Report on Form 8-K. The company clarified that the information shared is not considered ‘filed’ under the Securities Exchange Act of 1934 unless explicitly stated in future filings.

Spark’s Take on ABEO Stock

According to Spark, TipRanks’ AI Analyst, ABEO is a Neutral.

Abeona Therapeutics faces substantial financial hurdles with negative cash flows and no revenue growth. The potential for FDA approval and high revenue from pz-cel offer a positive outlook, yet initial supply constraints and increased expenses present risks. Technical analysis indicates limited momentum, and the negative valuation metrics reflect challenges typical for a biotech at this stage.

To see Spark’s full report on ABEO stock, click here.